Swift Biosciences Overview
- Year Founded
-
2010
- Status
-
Acquired/Merged
- Employees
-
45
- Latest Deal Type
-
M&A
- Investors
-
1
Swift Biosciences General Information
Description
Developer of novel molecular biology platform designed to characterize and understand the human genome. The company's platform examines disease-related genes, as well as improve next-generation sequencing sample preparation for Illumina and Ion Torrent and accelerate sample preparation for DNA sequencing, enabling clients to have more usable data from next-generation sequencing instruments.
Contact Information
Website
www.swiftbiosci.comCorporate Office
- 674 South Wagner Road
- Suite 100
- Ann Arbor, MI 48103
- United States
Corporate Office
- 674 South Wagner Road
- Suite 100
- Ann Arbor, MI 48103
- United States
Swift Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 11-Mar-2021 | Completed | Generating Revenue | |||
| 9. Debt - PPP | 15-Apr-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series E) | 13-Nov-2018 | Completed | Generating Revenue | |||
| 7. Accelerator/Incubator | 18-Jun-2018 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series D) | 12-Jun-2017 | Completed | Generating Revenue | |||
| 5. Later Stage VC (Series C) | 15-Apr-2016 | Completed | Startup | |||
| 4. Early Stage VC (Series B1) | 10-Sep-2015 | Completed | Startup | |||
| 3. Early Stage VC (Series B) | 16-Oct-2013 | Completed | Startup | |||
| 2. Early Stage VC (Series A1) | 16-Feb-2013 | $2.86M | $6.29M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 12-Aug-2010 | $3.43M | $3.43M | Completed | Startup |
Swift Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | ||||||||
| Series A1 | 1,895,338 | $0.010000 | $0.12 | $1.48 | $1.48 | 1x | $1.48 | 0.68% |
| Series A | 2,691,068 | $0.010000 | $0.1 | $1.27 | $1.27 | 1x | $1.27 | 0.96% |
Swift Biosciences Comparisons
Industry
Financing
Details
Swift Biosciences Competitors (24)
One of Swift Biosciences’s 24 competitors is Diagenode, a Formerly VC-backed company based in Seraing, Belgium.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Diagenode | Formerly VC-backed | Seraing, Belgium | ||||
| Oxford Nanopore Technologies | Formerly VC-backed | Oxford, United Kingdom | ||||
| Agendia | Venture Capital-Backed | Irvine, CA | ||||
| Autogenomics | Formerly VC-backed | Carlsbad, CA | ||||
| Agena Bioscience | Formerly PE-Backed | San Diego, CA |
Swift Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Swift Biosciences Patents
Swift Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021232023-A2 | Methods for ligation-coupled-pcr | Inactive | 15-May-2020 | ||
| WO-2021232023-A3 | Methods for ligation-coupled-pcr | Inactive | 15-May-2020 | ||
| WO-2020041702-A1 | Asymmetric targeted amplification methods | Inactive | 24-Aug-2018 | ||
| WO-2020010124-A2 | Temperature controlled dna polymerase inhibitors | Inactive | 02-Jul-2018 | ||
| WO-2020010124-A3 | Temperature controlled dna polymerase inhibitors | Inactive | 02-Jul-2018 | A61K31/7088 |
Swift Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Swift Biosciences Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Ann Arbor SPARK | Accelerator/Incubator | |||
| Arboretum Ventures | Venture Capital | Minority | ||
| Charter Private Capital Management | PE/Buyout | Minority | ||
| Fletcher Spaght Ventures | Venture Capital | Minority | ||
| Mercury Fund | Venture Capital | Minority |
Swift Biosciences FAQs
-
When was Swift Biosciences founded?
Swift Biosciences was founded in 2010.
-
Where is Swift Biosciences headquartered?
Swift Biosciences is headquartered in Ann Arbor, MI.
-
What is the size of Swift Biosciences?
Swift Biosciences has 45 total employees.
-
What industry is Swift Biosciences in?
Swift Biosciences’s primary industry is Diagnostic Equipment.
-
Is Swift Biosciences a private or public company?
Swift Biosciences is a Private company.
-
What is Swift Biosciences’s current revenue?
The current revenue for Swift Biosciences is .
-
How much funding has Swift Biosciences raised over time?
Swift Biosciences has raised $38.3M.
-
Who are Swift Biosciences’s investors?
Ann Arbor SPARK, Arboretum Ventures, Charter Private Capital Management, Fletcher Spaght Ventures, and Mercury Fund are 5 of 8 investors who have invested in Swift Biosciences.
-
Who are Swift Biosciences’s competitors?
Diagenode, Oxford Nanopore Technologies, Agendia, Autogenomics, and Agena Bioscience are some of the 24 competitors of Swift Biosciences.
-
When was Swift Biosciences acquired?
Swift Biosciences was acquired on 11-Mar-2021.
-
Who acquired Swift Biosciences?
Swift Biosciences was acquired by Integrated DNA Technologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
